Navigation Links
Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
Date:11/20/2008

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) will host a teleconference call today at 2:30 p.m. EST to review its drug development programs and financial results for the third quarter of 2008. Duska's chief executive officer, James S. Kuo, MD, MBA, will host the call and there will be a question-and-answer session immediately afterward.

To participate in the teleconference, please call toll-free 800.895.0198 (direct dial 785.424.1053) five minutes prior to the scheduled starting time in order to register for the call. A replay of the call will be available after its completion for ten days at 800.283.8217 (direct dial 402.220.0868).

"We have made remarkable progress in our two lead drug development programs this past quarter as we prepare for a Phase 2 trial for one compound and a Phase 3 trial for the other early next year," said Dr. Kuo. "In addition, we strengthened the intellectual property position around our ATPotent program through licenses with several inventors."

    Highlights of accomplishments included:

    -- Submission of a pivotal Phase 3 ATPace clinical trial protocol for
       review under a Special Protocol Assessment (SPA) procedure with the
       U.S. Food and Drug Administration (FDA).

       Subject to securing an agreement with the FDA, Duska intends to
       initiate a single, prospective, double-blind, placebo-controlled and
       randomized Phase 3 clinical trial with ATPace, its lead product. The
       trial will be aimed at demonstrating clinical safety and efficacy of
       ATPace in treating emergency room patients presenting with paroxysmal
       supraventricular tachycardia (PSVT).  PSVT is a condition characterized
       by a rapid, regular heart rate originating in the atria, which affects
       approximately 570,000 patients in the United States alone; in addition,
       89,000 new cases per 
'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
2. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
3. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
4. Duska Therapeutics Obtains Standard & Poors Listing
5. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
6. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
7. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
8. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
9. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... “We are honored to be named to this ... of Radiant Sage. “We are offering truly ground-breaking clinical ... market to a different level. We are enabling ... and effectively manage the massive amounts of medical imaging ... read by trained physicians. Being recognized by technology industry ...
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that the ... 28, 2010 , after the market closes. The press release will be followed ... open to the public via telephone and webcast. During the conference call, the ... , , ...
... EXTON, Pa. , July 21 ViroPharma Incorporated,s (Nasdaq: VPHM ... Wednesday, July 28, 2010 before the open of the U.S. financial markets. , ... The company will host a conference call and live ... the conference call, ViroPharma management will discuss the 2010 second quarter financial results and ...
... RESEARCH TRIANGLE PARK, N.C. , July 21 Chimerix, ... it has expanded its clinical management team with the appointment of ... and Herve Mommeja-Marin, MD, as Vice President of Clinical Research.   ... In these ...
Cached Biology Technology:Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast 2ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 3
(Date:8/27/2014)... CHICAGO , Aug. 27, 2014 /PRNewswire-iReach/ -- The ... hosting the 36 th Annual International Conference (EMBC,14), ... and Towers in Chicago, Illinois , ... than 2,500 global leaders, students, and industry professionals in ... Logo - http://photos.prnewswire.com/prnh/20140827/140333 ...
(Date:8/27/2014)... But every creature is a baby once. , A ... 24 very young dinosaurs and one older individual is ... caretaker, according to a new study by University of ... Dodson led the work, collaborating with researchers from China,s ... held. Hedrick is a doctoral student in the School ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... canary in the coal mine, penguins are sounding ... world,s oceans, and the culprit isn,t only climate ... Oil pollution, depletion of fisheries and rampant ... penguin species, along with Earth,s warming climate, are ...
... current standard practice of giving infants and children 100 ... deprivation may actually inflict additional harm, researchers at UT ... by oxygen deprivation, known as hypoxic-ischemic brain injury, is ... long-term neurological damage among infants and children. This can ...
... Twelve investigators have received grants totaling $5 million ... of food allergy, a significant public health concern. ... is funded by the National Institute of Allergy ... Institutes of Health, and two advocacy groups, the ...
Cached Biology News:Penguins setting off sirens over health of world's oceans 2Penguins setting off sirens over health of world's oceans 3Penguins setting off sirens over health of world's oceans 4Resuscitation technique after brain injury may do more harm than good 2NIAID announces grants to stimulate food allergy research 2NIAID announces grants to stimulate food allergy research 3
... a commonly used technique for studying protein ... electrophoresed on SDS-PAGE and transferred to a ... they are probed with specific antibodies. Unlike ... of Southern and Northern blots, it has ...
... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 amino ... human DNA fragmentation factor (DFF). The sequence of this ... P - K - S - V - K - ... S - P - R - K(18). This ...
Biology Products: